Last reviewed · How we verify
Phase II - Mirdametinib
At a glance
| Generic name | Phase II - Mirdametinib |
|---|---|
| Sponsor | Centre Georges Francois Leclerc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia (PHASE2)
- A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma (PHASE1, PHASE2)
- A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (PHASE2)
- SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma (PHASE1, PHASE2)
- Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %. (PHASE1, PHASE2)
- Mirdametinib in Histiocytic Disorders (PHASE2)
- Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC (PHASE1, PHASE2)
- Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phase II - Mirdametinib CI brief — competitive landscape report
- Phase II - Mirdametinib updates RSS · CI watch RSS
- Centre Georges Francois Leclerc portfolio CI